文献速递炎症性肠病

组织学缓解对已达内镜缓解的溃疡性结肠炎患者无额外获益

Histologic remission does not offer additional benefit for ulcerative colitis patients in endoscopic remission.
PubMed 文献 · Aliment Pharmacol Ther · 2020-11-01

这项回顾性观察性数据库研究纳入269例达内镜缓解(Mayo内镜子评分0)的溃疡性结肠炎患者,评估组织学活动度与复发时间的关系。Kaplan-Meier曲线显示组织学活动有无与复发时间无显著差异(log rank P=0.85),组织学活动性结肠炎与不活动性结肠炎相比临床复发时间无差异(AHR 1.17,95%CI 0.58-2.32,P=0.67)。结论认为组织学缓解不影响已达内镜缓解患者的复发时间。

要点

  • 内镜缓解的UC患者中,组织学活动有无与复发时间无显著差异(log rank P=0.85)。
  • 组织学活动性结肠炎与不活动性结肠炎相比,临床复发时间无差异(AHR 1.17,95%CI 0.58-2.32,P=0.67)。
  • 5-氨基水杨酸使用、全结肠炎、左半结肠炎和年龄较大与临床复发时间缩短显著相关。

核心结论

  • 组织学缓解不影响已达内镜缓解的溃疡性结肠炎患者的复发时间。

研究设计与样本

  • 回顾性研究,使用观察性数据库,纳入269例达内镜缓解(Mayo内镜子评分0)的溃疡性结肠炎患者,以首次达内镜缓解的结肠镜检查为索引结肠镜,组织学活动度分为正常、不活动性或活动性结肠炎,主要结局为复发时间。

主要发现

  • Kaplan-Meier生存曲线显示组织学活动有无与复发时间无显著差异(log rank P=0.85)。
  • 组织学活动性结肠炎与不活动性结肠炎相比,临床复发时间无差异(AHR 1.17,95%CI 0.58-2.32,P=0.67)。
  • 5-氨基水杨酸使用(AHR 0.42,95%CI 0.21-0.82,P=0.011)、全结肠炎(AHR 0.32,95%CI 0.13-0.75,P=0.008)、左半结肠炎(AHR 0.46,95%CI 0.22-0.98,P=0.044)和年龄较大(AHR 0.96,95%CI 0.94-0.99,P=0.002)与临床复发时间缩短显著相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Histologic remission in ulcerative colitis (UC) patients may be associated with positive outcomes. It is unclear whether UC patients in endoscopic remission obtain additional benefit from achieving histologic remission. AIM: To evaluate the relationship between time to relapse and histological activity among UC patients in endoscopic remission. METHODS: In this retrospective study using an observational database, we identified UC patients who had achieved endoscopic remission (Mayo endoscopic subscore 0). Index colonoscopy was the first colonoscopy when endoscopic remission was achieved. Histologic activity was classified as normal, inactive or active colitis. The primary outcome was time to relapse. Secondary outcomes included reasons for relapse and the association between baseline variables and risk of relapse. A Cox proportional hazards model evaluated baseline factors and the outcome of relapse. RESULTS: We included 269 patients. The Kaplan-Meier survival curve showed no significant difference between the presence or absence of histologic activity and time to relapse (log rank P = 0.85). There was no difference in time to clinical relapse of patients with histologically active colitis compared to inactive colitis (adjusted hazard ratio [AHR] 1.17, 95% CI 0.58-2.32, P = 0.67]). 5-aminosalicylate use (AHR 0.42, 95% CI 0.21-0.82, P = 0.011), pancolitis (AHR 0.32, 95% CI 0.13-0.75, P = 0.008), left-sided colitis (AHR 0.46; 95% CI 0.22-0.98; P = 0.044) and older age (AHR 0.96, 95% CI 0.94-0.99, P = 0.002) were significantly associated with reduced time to clinical relapse. CONCLUSION: Histologic remission did not influence time to relapse in UC patients who had achieved endoscopic remission.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Narula N, Aruljothy A, Alshahrani AA, et al. Histologic remission does not offer additional benefit for ulcerative colitis patients in endoscopic remission. Aliment Pharmacol Ther. 2020. PMID: 33131108. doi:10.1111/apt.16147

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。